Integra LifeSciences Holdings Corporation

NasdaqGS:IART Aktierapport

Börsvärde: US$1.8b

Integra LifeSciences Holdings Förvaltning

Förvaltning kriterier kontrolleras 2/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Mojdeh Poul

Verkställande direktör

n/a

Total ersättning

VD-lön i procentn/a
Anställning som VDless than a year
Ägande av VDn/a
Ledningens genomsnittliga anställningstid4.6yrs
Styrelsens genomsnittliga mandatperiod11.8yrs

Senaste uppdateringar av ledningen

Recent updates

Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade)

Mar 06

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Extensively

Jan 31
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Extensively

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Nov 05
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Oct 24
Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Sep 08
Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Aug 21
Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Jul 01
At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Jun 21

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

VD OCH KONCERNCHEF

Mojdeh Poul (60 yo)

less than a year

Anställning

Ms. Mojdeh Poul is President, CEO & Director of Integra LifeSciences Holdings Corporation from January 6, 2025. Ms. Poul serves as Independent Director at iRhythm Technologies, Inc. since June 1, 2023. She...


Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Stuart Essig
Non- Executive Chairman27.3yrsUS$422.52k2.27%
$ 40.3m
Lea Knight
Executive VP & CFO1.8yrsUS$1.67m0.054%
$ 964.6k
Jeffrey Mosebrook
Senior VP of Finance & Principal Accounting Officer7.4yrsUS$1.25m0.047%
$ 829.9k
Eric Schwartz
Executive VP6.3yrsUS$1.62m0.077%
$ 1.4m
Robert Davis
Executive VP & President of Tissue Technologies12.3yrsUS$1.42m0.084%
$ 1.5m
Michael McBreen
Executive VP & President of Codman Specialty Surgical4.8yrsUS$2.83m0.073%
$ 1.3m
Mojdeh Poul
Presidentless than a yearinga uppgifteringa uppgifter
Stephen Leonard
Corporate VP of Global Operations & Supply Chain4.6yrsinga uppgifteringa uppgifter
Christopher Ward
Senior Director of Investor Relationsno datainga uppgifteringa uppgifter
Laurene Isip
Vice President of Global Corporate Communications & Public Relationsno datainga uppgifteringa uppgifter
Ruth Fleming
Vice President of Global Marketingno datainga uppgifteringa uppgifter
Chantal Veillon-Berteloot
Executive VP & Chief Human Resources Officer2.2yrsinga uppgifter0.032%
$ 560.7k

4.6yrs

Genomsnittlig anställningstid

58yo

Genomsnittlig ålder

Erfaren ledning: IART s ledningsgrupp anses vara erfaren ( 4.6 års genomsnittlig anställningstid).


Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Stuart Essig
Non- Executive Chairman27.3yrsUS$422.52k2.27%
$ 40.3m
Mojdeh Poul
Presidentless than a yearinga uppgifteringa uppgifter
Raymond Murphy
Independent Director15.9yrsUS$297.54k0.11%
$ 1.9m
Christian Schade
Independent Director19.2yrsUS$293.28k0.082%
$ 1.5m
Barbara Hill
Independent Presiding Director11.8yrsUS$342.54k0.18%
$ 3.1m
Keith N. Bradley
Independent Director33.2yrsUS$306.31k0.091%
$ 1.6m
Jeffrey Graves
Independent Director1.3yrsUS$90.68k0.016%
$ 287.4k
Shaundra Clay
Independent Director3.9yrsUS$260.04k0.028%
$ 504.2k
Renee Lo
Independent Director2.7yrsUS$297.54k0.021%
$ 371.5k

11.8yrs

Genomsnittlig anställningstid

63yo

Genomsnittlig ålder

Erfaren styrelse: IART s styrelse är rutinerade och erfaren ( 11.8 års genomsnittlig mandatperiod).


Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2025/03/09 07:45
Aktiekurs vid dagens slut2025/03/07 00:00
Intäkter2024/12/31
Årlig intjäning2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Integra LifeSciences Holdings Corporation bevakas av 31 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
David ToungArgus Research Company
Matthew TaylorBarclays
Charley JonesBarrington Research Associates, Inc.